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Liver Transplantation 
Gilbert J. Burckart, PharmD, FCP, Raman Venkataramanan, PhD, 
Richard J. Ptachcinski, PharmD, Thomas E. Starzl, MD, J. Carlton Gartner, Jr, MD, 
Basil J. Zitelli, MD, Jeffrey J. Malatack, MD, Byers W. Shaw, MD, 
Shunzaburo Iwatsuki, MD, and David H. Van Thiel, MD 
Blood concentrations of cyclosporine were determined in adult and pediatric patients 
following orthotopic liver transplantation to quantitatecyclosporine blood clearance and 
oral absorption. Seventeen bioavailability studies were performed following transplanta-
tion surgery in nine children and seven adults. The intravenous cyclosporine study was 
performed following an average dose of 2.1 mg(kg. The patients were again studied when 
they received the same intravenous dose plus an oral dose of cyclosporine of B.6 mg/kg or 
an oral dose alone. Blood samples were collected and analyzed for cyclosporine using 
high-performance liquid chromatography. Cyclosporine blood clearance ranged from 29 
to 203 mLimin (1.9-21.5 mLiminlkg) in children and from 253 to 6Bo mLimin (3.2-7.6 
mLlminlkg) in adults. The mean cyc1osporine clearance value was 9.3 mL/minlkg in the 
pediatric patients and 5.5 mLlminlkg in the adults. Cyclosporine bioavailability was less 
than 5% in six studies on five pediatric patients in the immediate postoperative period. 
The bioavailability varied from 8% to 60% in adult liver transplant patients (mean, 270/0). 
We conclude that: (1) cyclosporine clearance is highly variable between patients, (2) 
pediatric patients clear the drug more rapidly than adults and therefore need a higher 
cyc1osporine dose on a body weight basis, (3) cyclosporine is poorly and variably absorbed 
in liver transplant patients, and{4} cyclosporine blood concentration monitoring is 
essential following orthotopic liver transplantation. 
O rthotopic liver transplantation is now considered a 
therapeutic alternative for children with diseases such 
as biliary atresia and alpha1-antitrypsin defrciency and for 
adults with primary biliary cirrhosis and sclerosing cholan-
gitiS.1- 5 Therapy with cyclosporine and low-dose steroids 
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constitutes a major advance in the treatment of patients 
undergoing orthotopic liver transplantation.6 
Liver transplantation presents special problems in main-
taining adequate pharmacologic immunosuppression. The 
absorption, metabolism, and excretion of pharmacologic 
agents can be expected to be significantly altered by the 
transplantation procedure. Aggressive drug therapy is often 
needed to achieve adequate immunosuppression. 
Adequate blood concentrations of cyc1osporine are main-
tained following orthotopic liver transplantation by pro-
longed intravenous (IV) and combined IV and oral therapy. 
This cyclosporine dosing regimen is different than that used 
following renal or heart transplantation and prompted us to 
investigate the clearance and bioavailability of cyclosporine 
following orthotopic liver transplantation. 
PATIENTS AND METHODS 
All patients who underwent orthotopic liver transplantation 
were considered candidates for the study. Seventeen stud-
ies were performed after patient (seven adults) or parental 
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jc CYCLOSPORINE ABSORPTION 
I 
[nine children J consent was obtained. Fifteen patients 
received the same intravenous cyclosporine dosage every 
eight hours for at least 24 hours before the start of the 
study. 
Protocol 
f~ On the first study day. the patients received their prescribed 
~ IV cyclosporine dosage infused over two hours by Harvard 
t infusion pump (Bard Medical Systems. North Reading. MAJ 
}'i or an IV drip set. In the ten pediatric studies. heparinized 
.' : blood samples were obtained before the start of the infu-
( sian. at the end of the infusion. and at four. six. and eight 
'\ hours followipg the start of the infusion. Hourly blood 
" samples were collected during the dosing interval in adults. 
J' On the second study day. ten children and two adults 
1 received the same IV dose of cyclosporine at the same time '" of the day. but also received an oral cyclosporine dose 
, concurrent with the start of the infusion. Five adult patients 
,). received only oral cyclosporine q12h on the second day. 
The oral r;yclosporine liquid was diluted with juice or 
chocolate milk. mixed. and' administered as quickly as 
possible. The blood sampling on the second day followed 
\ the same schedule as that of the first day. with the exception 
f,r. that the adult patients were sampled hourly for 12 hours. 
e"" , Concurrent medications administered with cyclosporine 
• ,'" included methylprednisolone or prednisone. cefotaxime 
,: ,a,nd ampicillin. captropril. hydralazine. furosemide. and 
"nystatin. 
ill,:,',':,:: ",,"pI., w~" "fIigII~tId at 4·C until a.""y,d {<7 g~/davpgK An ~xtractllnK a~d a hIgh-performance lIqUId ch:o-
'\' f:,.matographrc assay SImIlar to that of Sawchuk and Cartier t1\Vasused.7 The assays were perform~d using whole blood. 
1\" ,2andcyclosporin D was the internal standard. The drug was 
f' 'initially extracted into diethyl ether. After drying. the 
'/" residue was taken up in methanol. combined with hydro-
chloric acid. and washed twice with hexane. After neutral-
j' ization. the drug and internal standard were' reextracted into ether, dried, and reconstituted with the mobile phase 
"before injection. The samples were injected onto a 15-cm 
: ~;IDC~1U column (Supelco, Bellefonte. PAJ maintained at 70o e. 
V:The-mobile phase was 680/0 acetonitrile in water with a flow 
!':ra.te of 1.5 mLimin. Ultraviolet detection was achieved at 
" t:'t'214nm with a Model 441 detector (Waters. Milford. MA). 
~i!;Afisamples and standards were analyzed in duplicate. The 
i~ID:retentiori times for cyclosporine and cyclosporin D were 8.3 
t>~~d U.2 minutes, respectively, The minimum detectable 
1'.,,:',,:lev,el of this assay is 25 ng/mL using one mi.lliliter of blood. EKI~tandard curves were run from concentratIOns of 50-2.000 
~D;~g/tniK The interday coefficient of variation of the assay 
I~~Eas 8.00/0 at 250 ng/mL (N = 35J. 6.40/0 at 500 ng/mL It"'" 19). and 7.7% at 1.000 ng/mL (N = 23J. 
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Data Analysis 
The short dosing interval precluded calculation of a half-
life or elimination rate constant. All studies were carried out 
at steady-state or pseudo-steady-state conditions. The area 
under the curve (AUC] for the blood concentration versus 
time curve was calculated by the trapezoidal rule over' one 
dosing interval. Drug clearance was calculated as the IV 
cyclosporine dose divided by the Aue (IVJ and bioavail-
ability percentage (F) was calculated as: 
F __ AUe (IV + oral) - AUC [IVJ X dose (IV) 
---'--'-- X 100 or 
AUC (rV) dose [oralJ 
F Aue (oralJ dose (rV) 
= X X 100 
AUC (IV) dose (oralJ 
Rank correlation of subgroups were compared using the 
Wilcoxon two-tailed analysis assuming a level of signifJ.-
cance of P :5 .05. 
RESULTS 
The characteristics of the patients at the time of study are 
listed in Table 1. Patient 7 was studied twice after two 
separate transplant operations. Nine of the studies were 
performed after the fust orthotopiC liver transplantation, 
seven after the second. and one after the third operation. 
Nine of the studies were started on the second or third day 
postoperatively. 
The maximum blood concentration after the IV cyclospo-
rine was observed at the end of the infusion and the blood 
concentration declined in a biexponential fashion. Figures 1 
and 2 present the blood concentration versus time for a 
representative adult and pediatric patient. Table II lists the 
estimated pharmacokinetic' parameters derived frpm the 
blood concentration versus time data. The average cyclo-
sporine dosage was 2.1 mg/kg IV and 8.6 mg/kg orally. The 
mean trough concentration at eight hours was 298 ng/mL 
following IV cyclosporine in the pediatric patients. Four of 
the pediatric patients had a cyclosporine clearance of 
greater than 10 mLimin/kg. The clearance of cyclosporine 
in the adult patients ranged from 3.2 to 7.6 mUmin/kg. The 
mean cyclosporine clearance was 9.3 mLimin/kg in the 
pediatric population and 5.5 mLimin/kg in the adults. 
Six studies conducted in the pediatric study population in 
the immediate postoperative period demonstrated an esti-
mated bioavailability of less than 50/0 of the orally adminis-
tered cyclosporine. In these patients. cyclosporine clear-
ance was less than 10 mL/min/kg. The other four children 
with bioavailability greater than 50/0 had cyclosporine blood 
clearances greater than 10 mL/min/kg (P = .01J. A wide 
variation in the extent of absorption in adult patients was 
observed as indicated by a bioavailability of 80/0 to 600/0 
(mean ± standard deviation = 27 ± 180/0). The two adults 
with an 80/0 and 150/0 bioavailability had a serum bilirubin 
648 
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-TABLE I 
Patient Characteristics 
Postoperative Day on 
Which Study Was Performed 
Patient Age Weight (kg) Original Diagnosis IV IV + PO PO 
1 34 mo 11.4 f3iliary atresia 2 3 
2 67 mo ~SKU ai-antitrypsin deficiency 8 9 
3 52 mo 12.3 Biliary atresia 3 4 
4 39 mo 15.5 Biliary atresia 3 4 
5 11 mo 8.2 Biliary atresia 2 3 
6 51 mo 17.9 Biliary atresia 3 4 
7a 36 mo 15.3 Hepatitis 3 4 
7b 37 mo 14.4 Hepatitis 2 3 
8 47 mo 14.3 Biliary atresia 2 3 
9 7 mo 7.0 Biliary atresia 2 3 
10 47 yr 52 Primary biliary cirrhosis 3 43 
11 21 yr 40 Tyrosinemia. hepatoma 2.' 24 
12 42 yr 88 Post-necrotic cirrhosis 18 29 
13 26 yr 70 Hepatitis. cirrhosis 5 56 
14 51 yr 55 Prirnary biliary cirrhosis 2. 49 
15 27 yr 96 Post-necrotic cirrhosis 2. 21 
16 36 yr 61 Chronic active hepatitis 29 30 
IV = intravenous; PO = oral. 
concentration of greater than 2.0 mg/dL. whereas the five 
adult patients with greater cyclosporine absorption had a 
serum bilirubin of less than 2.0 mg/dL. The serulIl bilirubin 
concentration was greater than 3.6 mg/dL in all the pediat-
ili~~~ . 
DISCUSSION 
The pharmacokinetics of cyclosporine have been investi-
gated in the recipients of allogenic bone marrow grafts and 
transplanted kidneys and hearts. The harmonic mean 
cyclosporine blood clearance in kidney transplant recipi-
ents is 5.7 mL/min/kg [range. 0.6-23.9 mLimin/kg).B The 
plasma clearance of the drug was previously determined to 
be 12.2 ± 5.6 mLimin/kg in bone marrow transplant 
patients.9 whereas the blood clearance ranged from 2.1 to 
15.1 mLimin/kg in patients receiving heart transplants.10 In 
each of these patient populations. the clearance values are 
highly variable. 
In the present study, a tenfold variation in the clearance 
of cyclosporine was observed in pediatric liver transplant 
patients. The day to day variability in clearance in an 
individual patient has not been assessed and may have 
contributed in part to this variation. Pediatric patients had a 
higher harmonic mean cyclosporine clearance per body 
weight as compared with adult liver transplant patients, 
even though they were studied earlier in their course of 
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therapy. The' highest cyclosporine clearance value (21.5 
mL/min/kg) was noted in the youngest study patient (age, 7 
months). The higher cyclosporine clearance in children is 
consistent with the observations of higher clearance per 
bpdy weight Qf other drugs such as theophylline in the 
pediatric population11 and with, our studies of cyclosporine 
in pediatric kidney and heart transplant patients.12 Pediatric 
renal transplant patients have the highest cyclosporine 
blood clearance values. with a harmonic mean clearance of 
11.8 mLimin/kg.13 The higher cyclosporine clearance in 
children is consistent with the higher drug doses on a body 
weight basis that are frequently necessary to achieve blood 
concentrati~ns similar to those seen in adults. 
Studies in bone marrow and kidney transplant patients 
have shown considerable vqriation in the peak plasma 
levels cif cyclosporine following oral administration of the 
drug.14.15 The bioavailability of cyclosporine has been 
reported to range from 100/0 to 500/0, with a mean of 340/0.16 
We have observed an average bioavailability of 27.60/0 in 41 
renal transplant patients in whom a marked variation in the 
bioavailability of cyclosporine has also been observed 
(range. <50/0 to 890/0 ).B 
Because of the limitations in the study design imposed by 
this patient population. the bioavailability parameters cal-
culated are only estimates of the actual bioavailability 
values. We most likely underestimated bioavailability if 
hepatic drug clearance had improved on the oral study day, 
, 
I. _------------~CvCilpmlofkb ABSORPTIO\J 
3 
~9 
i6 
1-9 
30 
:1.5 
S, 7 
1 is 
per 
the 
cine 
ltric 
rine 
:e of 
e in 
)ody 
load 
ients 
lsma 
f the 
been 
1 % .16 
in 41 
nthe 
3rved 
edby 
's cal-
lbility 
lity if 
yday. 
t , 
J: 
J , 
, 
I 
I 
'( 
I 
E 
.... 
'" 
=-z. 
0 
s 
a: 
t-
z. 
<oJ 
u 
z. 
0 
0 
Cl 
0 g 
al 
5000 
3000 
1000 
500 
I 
f 
I 
I 
I 
I 
I 
I 
I 
I 
X 
I 
I 
x-
I 
x--x 
\ 
\ 
\ 
\ 
"-
'x , 
, 
, 
300 t !! ! 
~M----~O----~4-----S~---U~---1~M----1Oi----
TIME (HRS) 
Figure 1. Cyc1osporine blood concentration versus time in adult 
:study patient 16. Concentrations following an intravenous (e--e) 
and an oral (x - -xl dose are presented. 
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:Figure 2. Cyc1osporine blood concentrotion versus time in pediatric 
patient 6. Concentrations following an intravenous (e--e) 
intravenous plus oral (x - - x) dose are presented. 
. may have overestimated bioavailability if steady state 
not been achieved at the time of the intravenous study. 
vehicle used to dilute the drug (juice or milk) will not 
""'s1iQOV;'p'1<>T' affect drug absorption.17 Changes in drug clear-
between the intravenous and oral study would also 
the bioavailability estimate. 
NICAL RESEARCH: IMMUNOSUPPRESSIVE DRUGS 
In the pediatric orthotopic liver transplantation patients. 
cyclosporine was very poorly absorbed. The bioavailability 
ranged from <50/0 to 18%. The poor absorption of cyclospo-
rine in our· pediatric orthotopic liver transplantation recipi-
ents was predictable from.our previous clinical experience. 
However. we did not anticipate such a large variation in the 
absorption in the immediate postoperative period. This 
observation indicates that not all orthotopic liver transplan-
tation patients require prolonged intravenous therapy. The 
early initiation of oral cyclosporine in conjunction with the 
intravenous formulation while monitoring trough blood 
concentrations is an effective test of drug absorption. This 
regimen facilitates the early conversion from intravenous to 
oral therapy with cyclosporine in those patientS who ade-
quately absorb the drug. 
In contrast with the poor cyclosporine absorption 
observed in our pediatric population iri the immediate 
postoperative period. adults with improving liver function 
following orthotopic liver transplantation absorbed 8% to 
60% of an oral cyclosporine dose. Cyclosporine bioavail-
ability has been reported to increase three- to fivefold over 
a three-month time period in renal transplant patients.15 
Improving liver function and bile flow in liver transplant 
recipients may be responsible for improving cydosporine 
absorption over time and may permit a dosage reduction. 
Increases in the trough blood concentrations of cyclospo-
rine. are particularly notable fonowing T-tube damping in 
TABLE II 
Cyclosporine Pharmacokinetic Parameters 
Dose 
(mg/kg) Clearance. Bioavailability 
Patient IV Oral (mL/min/kg) (%) 
1 2.6 8.8 13.0 13 
2 1.8 8.9 12.1 18 
3 2.4 8.1 7.1 <5 
4 1.9 8.1 1.9 <5 
5 3.7 18.3 8.2 <5 
6 2.0 8.4 10.4 19 
7a 1.6 9.2 6.0 <5 
7b 2.1 10.4 6.9 <5 
8 3.1 7.0 5.6 <5 
9 2.0 8.6 21.5 8 
10 1.7 9.6 4.9 10 
11 1.8 10.0 6.3 60 
12 0.6 3.4 3.2 29 
13 2.1 3.6 5.3 15 
14 2.0 7.3 7.6 38 
15 1.9 7.3 7.1 8 
16 2.5 7.4 4.4 31 
IV = intravenous. 
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orthotopic liver transplantation patients.18 Previous studies 
have shown this increase is not attributable to increased 
enterohepatic recycling of cyclosporine following T -tube 
clamping.19 Increased bile flow into the gut is most likely 
responsible for the improved cyclosporine absorption. 
Cyclosporine absorption did not correlate with serum 
biochemical parameters such as bilirubin or liver enzyme 
levels in the immediate postoperative period. Gastric emp-
tying and gut motility were not assessed in this study but 
may affect bioavailability particularly in lhe immediate 
postoperative period. Estimates of hepatic bf~od flow were 
likewise not evaluated in this study. Subsequent investiga-
tions in adults with liver disease have demonstrated a good 
correlation between an elevated serum bilirubin concentra-
tion and a diminished cyclosporine bioavailability follow-
ing an oral dose.20 
The frequent malabsorption and the marked variability in 
cyclosporine absorption and metabolism makes individual-
ization of cyclosporine therapy essential in individuals 
undergoing orthotopic liver transplantation. Cyclosporine 
clearance on a body weight basis is high in some children 
and necessitates higher than normal doses of the drug based 
on body weight. Only a struCtured program of blood level 
monitoring can presently provide the essential information 
on cyclosporine absorption or metabolism following liver 
transplantation. An adequate monitoring program should 
include frequent (2-3 times weekly) blood sampling of 
cyclosporine levels during the early postoperative period 
and should recognize the limitations of the assay used.21 
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